Drugs / Dengue 1,2,3,4 (attenuated) vaccine
Dengue 1,2,3,4 (attenuated) vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06891950 | Mar 2026 → Mar 2027 expected | dengue disease | Butantan Institute | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dengue 1,2,3,4 (attenuated) vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06891950 ↗ |
| Known as | Butantan-dengue vaccine | “We assessed the safety and efficacy of the live, attenuated, tetravalent Butantan-dengue vaccine (Butantan-DV) in adults, adolescents, and children.” PMID 39116904 ↗ Aug 2024 |
| Known as | Butantan-DV | “We assessed the safety and efficacy of the live, attenuated, tetravalent Butantan-dengue vaccine (Butantan-DV) in adults, adolescents, and children.” PMID 39116904 ↗ Aug 2024 |
| Modality | Vaccine | “the live, attenuated, tetravalent Butantan-dengue vaccine” PMID 39116904 ↗ Aug 2024 |
| Route | Subcutaneous | “administered subcutaneously” PMID 39116904 ↗ Aug 2024 |